肿瘤病人rhIL-2/LAK细胞治疗前后的免疫功能变化  

THE CHANGE OF CELLULAR IMMUNE FUNCTION IN CANCER PATIENTS UNDERGOING rhIL-2 / LAK THERAPY

作　　者：王昌勤[1] 皇甫梅生[1] 徐岚[1] 孙恪遵 应奇峰[1] 史梅芳[2] 

机构地区：[1]浙江省人民医院生物治疗中心,杭州310014 [2]浙江省人民医院科教科,杭州310014

出　　处：《中国实验血液学杂志》1995年第4期422-426,共5页Journal of Experimental Hematology

摘　　要：对50例恶性肿瘤患者经rhIL-2/LAK细胞治疗前、后的免疫功能进行了动态观察。检测指标包括T细胞亚群(CD3,CD4,CD8和CD4/CD8)、淋巴细胞转化试验和单个核细胞细胞毒因子(MCCF)活性。结果表明,肿瘤患者经rhIL-2/LAK细胞治疗后,CD3和CD4比例明显升高,CD8也略有升高,CD4/CD8比值则明显升高;淋巴细胞转化率明显升高;MCCF活性明显增强。这反映肿瘤患者经rhIL-2/LAK细胞治疗后机体细胞免疫功能得到增强。Fifty malignant tumor patients were investigated for their cellular immune function follow-ing rhIL-2 / LAK therapy. It has been shown that Ievels of CD3 and CD4 subpopulations, CD4/CD8 ratio and LBT were significantly increased (P<0.01) compared with pretreatment Ievels by rhIL-2 / LAK therapy. The dynamic change of MCCF in cancer patients before or af-ter rhIL-2 / LAK therapy was also investigated. MCCF activity Ievel of pretreatment and normai control were 4.12 ±3.17% and 5.911 2.65%, respectively. On the third day after rhIL-2/LAK therapy it was significantly increased (56.67 ± 10.30%) (P<0.01). The results shovved that rhIL-2 / LAK therapy could improve cellular immune function of cancer patients.

关 键 词：白细胞介素2 LAK细胞 T细胞亚群 淋巴细胞转化试验 单个核细胞细胞毒因子 

分 类 号：R730.5[医药卫生—肿瘤]